Mainboard · BSE and NSEDraft filed
Encube Ethicals Limited IPO: dates, price band, lot size, objects of the issue
Get updates on this IPO
Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.Dates, allotment, listing and analyst views. Stop anytime.
By continuing you agree to the Terms and Privacy policy
Key facts
- Price band
- Not announced
- Lot size
- Not announced
- Lot amount at the upper band
- Not announced
- Issue size at the upper band
- ₹3,000.00 crore
- Bid dates
- Not announced
- Listing date
- Not announced
- Proposed exchanges
- BSE and NSE
Timeline (IST)
- Draft filedThu 6 Aug 2026 confirmedDRHP dated Sat 1 Aug 2026
- OpensDates to be announced
- ClosesDates to be announced
- AllotmentDates to be announced
- Refund and unblockDates to be announced
- ListingDates to be announced
Company and promoters
As described in the DRHP
We are a global pharmaceutical formulations platform with deep domain expertise in technically complex topical and transdermal dosage forms, serving 50 countries including regulated markets such as the United States, UK and Europe, and India as of March 31, 2026.
DRHP dated Sat 1 Aug 2026, page 229
Promoters
- 1 individual promoter
DRHP dated Sat 1 Aug 2026, page 300
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 80.91% | Not stated in the DRHP |
| Public | 19.09% | Not stated in the DRHP |
DRHP dated Sat 1 Aug 2026, page 119
Financials (restated)
| Item | Financial Year ended March 31, 2026 | Financial Year ended March 31, 2025 | Financial Year ended March 31, 2024 |
|---|---|---|---|
| Revenue from operations | ₹1,848.70 crore | ₹1,344.80 crore | ₹1,085.90 crore |
| Profit after tax | ₹436.70 crore | ₹249.60 crore | ₹156.10 crore |
| Net worth | ₹1,915.20 crore | ₹1,495.20 crore | ₹1,243.40 crore |
| Total borrowings | Not stated in the draft | Not stated in the draft | Not stated in the draft |
DRHP dated Sat 1 Aug 2026, page 90
Who is selling in the offer for sale
| Selling shareholder | Type | Shares offered | Amount at the upper band |
|---|---|---|---|
| Individual shareholder | Individual | Not announced | Not announced |
| Frontier Investment Holdings Pte. Ltd. | Company | Not announced | Not announced |
| Total offer for sale | ₹3,000.00 crore | ||
DRHP dated Sat 1 Aug 2026, page 1
Peer comparison (as in the DRHP)
| Name of the company | Standalone / consolidated | Total revenue from operations (₹ in million) | Face value (₹ per equity share) | Closing price of each equity share as on July 31, 2026 | P/E ratio (x) | EPS Basic (₹ per equity share) | EPS Diluted (₹ per equity share) | RoNW (%) | Net asset value per share (₹) |
|---|---|---|---|---|---|---|---|---|---|
| Our Company | Consolidated | 18,487 | 1 | [●]^ | [●]^ | 14.38 | 14.36 | 25.21% | 64.29 |
| Dr. Reddy’s Laboratories Limited | Consolidated | 3,37,002 | 1 | 1,147.60 | 22.79 | 50.41 | 50.35 | 11.75% | 453.98 |
| Lupin Limited | Consolidated | 2,79,580 | 2 | 2,413.95 | 20.73 | 116.75 | 116.44 | 26.90% | 489.98 |
| Zydus Lifesciences Limited | Consolidated | 2,71,484 | 1 | 1,126.50 | 22.49 | 50.09 | 50.09 | 19.74% | 269.43 |
| Aurobindo Pharma Limited | Consolidated | 3,36,531 | 1 | 1,579.35 | 26.17 | 60.34 | 60.34 | 9.94% | 652.39 |
| Glenmark Pharmaceuticals Limited | Consolidated | 1,69,825 | 1 | 2,233.30 | 46.30 | 48.26 | 48.24 | 14.07% | 372.33 |
| Alembic Pharmaceuticals Limited | Consolidated | 73,449 | 2 | 797.05 | 23.22 | 34.33 | 34.33 | 12.42% | 288.70 |
| Rubicon Research Limited | Consolidated | 17,540 | 1 | 1,492.60 | 97.49 | 15.52 | 15.31 | 26.97% | 77.10 |
| Gland Pharma Limited | Consolidated | 64,307 | 1 | 2,504.4 | 40.21 | 62.35 | 62.28 | 10.53% | 625.62 |
| OneSource Specialty Pharma Limited | Consolidated | 14,216 | 1 | 1,621.75 | NA | (6.44) | (6.44) | (1.26)% | 508.22 |
Reproduced from the DRHP dated Sat 1 Aug 2026, page 134; InsightPier adds no figures
Risk factors
83 total- Most revenue comes from the Global Generics and Global CDMO businesses; a slowdown in either could hurt results (DRHP page 26)
- Most products are made for markets outside India, mainly the United States and Europe, exposing the company to foreign-market risks (DRHP page 28)
- Manufacturing sites face regulator and customer inspections; a quality failure could bring regulatory action or lost contracts (DRHP page 29)
- Product quality concerns could lead customers and distributors to cancel orders or end agreements (DRHP page 31)
- Shares bought in the offer cannot be sold on an exchange immediately; listing could be delayed (DRHP page 85)